Espesor macular medido con tomografía de coherencia óptica en ojos pseudoafáquicos con implante amarillo vs. transparente / Macular thickness measured by optical coherence tomography in pseudoaphakic eyes with clear vs yellow implant

OBJETIVO: Evaluar mediante tomografía de coherencia óptica (OCT) las variaciones de espesor macular producidas a lo largo del tiempo en ojos pseudoafáquicos implantados con una lente intraocular (LIO) transparente en comparación con sus respectivos ojos contralarerales implantados con LIO amarilla. MÉTODOS: El espesor macular de 36 ojos de 18 sujetos fue evaluado mediante OCT. Los sujetos presentaban edades superiores a 65 años y habían sido intervenidos de cataratas en ambos ojos en 2 cirugías independientes. La principal característica de los individuos es que llevaban implantada una LIO con diferente absorción en cada ojo: transparente (absorbente de la radiación ultravioleta) y amarilla (con filtro adicional absorbente de las radiaciones violeta-azul del espectro visible). El espesor macular se evaluó en 2 sesiones separadas en el tiempo por un intervalo de tiempo de 5 años, mediante el sistema Stratus-OCT (protocolo fast macular thickness). Se analizaron estadísticamente las diferencias en la evolución del espesor macular entre ojos con diferente tipo de LIO. RESULTADOS: Tras 5 años de seguimiento, se observó que los ojos implantados con LIO transparente manifestaban una reducción del espesor macular estadísticamente significativa, superior a la esperada por el aumento de la edad. Sin embargo, los ojos implantados con LIOs amarillas mantuvieron su espesor macular estable. La disminución del espesor macular promedio en ojos implantados con LIO transparente fue de 5 ± 8 μm (p = 0,02) y la reducción del espesor foveal fue de 10 ± 17 μm (p = 0,02). CONCLUSIONES: Los cambios de espesor macular producidos en ojos implantados con una LIO amarilla difieren de los cambios manifestados en ojos con LIO transparente. Estas observaciones apuntan a un posible efecto protector de las LIOs amarillas contra los efectos dañinos de la luz en sujetos pseudoafáquicos. Sin embargo, estudios con un mayor tamaño muestral y mayor tiempo de seguimiento son necesarios para confirmar que la protección inducida por este tipo de LIO es clínicamente significativa

OBJECTIVE: To study the use of optical coherence tomography (OCT), for measuring the macular thickness variations produced over time in elderly pseudophakic subjects implanted with a clear intraocular lens (IOL) in one eye, and a yellow IOL in the other eye. METHODS: Macular thickness measurements were obtained in the 36 eyes of 18 subjects over 65 years, with cataracts surgically removed from both eyes and implanted with different absorbance (clear and yellow) IOLs in 2 separate surgeries. Stratus-OCT was used to determine the macular thickness in 2 sessions with 5 years of difference. RESULTS: After 5 years of follow-up, the eyes implanted with clear IOLs revealed a significant decrease in macular thickness. However, in eyes implanted with yellow IOLs the macular thickness remained stable. The mean overall decrease in macular thickness in eyes implanted with clear IOLs was 5 ± 8 μm (P=0.02), and foveal thickness reduction was 10 ± 17 μm (P=0.02). CONCLUSIONS: The macular thickness changes produced in eyes implanted with a yellow IOL differ from those with a clear IOL. These observation point to a possible protective effect of yellow IOL against the harmful effects of light in elderly pseudophakic subjects. However, studies with a longer follow-up are still needed to confirm that the protection provided by this IOL model is clinically significant

[Macular thickness measured by optical coherence tomography in pseudoaphakic eyes with clear vs yellow implant]. / Espesor macular medido con tomografía de coherencia óptica en ojos pseudoafáquicos con implante amarillo vs. transparente.

OBJECTIVE: To study the use of optical coherence tomography (OCT), for measuring the macular thickness variations produced over time in elderly pseudophakic subjects implanted with a clear intraocular lens (IOL) in one eye, and a yellow IOL in the other eye. METHODS: Macular thickness measurements were obtained in the 36 eyes of 18 subjects over 65 years, with cataracts surgically removed from both eyes and implanted with different absorbance (clear and yellow) IOLs in 2 separate surgeries. Stratus-OCT was used to determine the macular thickness in 2 sessions with 5 years of difference. RESULTS: After 5 years of follow-up, the eyes implanted with clear IOLs revealed a significant decrease in macular thickness. However, in eyes implanted with yellow IOLs the macular thickness remained stable. The mean overall decrease in macular thickness in eyes implanted with clear IOLs was 5 ± 8 µm (P=.02), and foveal thickness reduction was 10 ± 17 µm (P=.02). CONCLUSIONS: The macular thickness changes produced in eyes implanted with a yellow IOL differ from those with a clear IOL. These observation point to a possible protective effect of yellow IOL against the harmful effects of light in elderly pseudophakic subjects. However, studies with a longer follow-up are still needed to confirm that the protection provided by this IOL model is clinically significant.

Siderosis bulbi. Presentación clínica de un caso de tres años de evolución / Siderosis bulbi. Clinical presentation of a case of three years from onset

Caso clínico: Se presentan las características clínicas y funcionales de un paciente de 30 años con siderosis bulbi de tres años de evolución, y el tratamiento mediante facoemulsificación y vitrectomía para la eliminación de los restos metálicos. Discusión: A pesar de que la mayoría de los cuerpos extraños intraoculares (CEIO) tienen un efecto deletéreo inmediato, en casos de cuerpos pequeños, localizados y con poca afectación visual, es posible su observación. Sin embargo, con el tiempo, el hierro se deposita en el epitelio pigmentado de la retina, produciendo cambios a nivel macular y periférico responsables de pérdida progresiva de visión. La cirugía de extracción del CEIO puede frenar la progresión de esta dolencia(AU)

Case report: The clinical and functional characteristics of a 30 years-old patient with three years-evolution siderosis bulbi are described in this paper, as well as the treatment using phacoemulsification and vitrectomy for the elimination of the metallic remains. Discussion: In spite of the fact that the majority of the intraocular foreign bodies (IOFB) have a dangerous immediate effect, in cases of small, local bodies and with little visual deterioration, observation is possible. Nevertheless, with time, the iron settles on the pigmented epithelium of the retina, producing changes at macula and peripheral level, which are responsible for the gradual loss of vision. The surgical removal of the IOFB can stop the progression of this pathology(AU)

[Siderosis bulbi. Clinical presentation of a case of three years from onset]. / Siderosis bulbi. Presentación clínica de un caso de tres años de evolución.

CASE REPORT: The clinical and functional characteristics of a 30 years-old patient with three years-evolution siderosis bulbi are described in this paper, as well as the treatment using phacoemulsification and vitrectomy for the elimination of the metallic remains. DISCUSSION: In spite of the fact that the majority of the intraocular foreign bodies (IOFB) have a dangerous immediate effect, in cases of small, local bodies and with little visual deterioration, observation is possible. Nevertheless, with time, the iron settles on the pigmented epithelium of the retina, producing changes at macula and peripheral level, which are responsible for the gradual loss of vision. The surgical removal of the IOFB can stop the progression of this pathology.

[Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD)]. / Guías de práctica clínica de la SERV: tratamiento de la degeneración macular asociada a la edad (DMAE) exudativa.

OBJECTIVE: Age related macular degeneration (ARMD) in its neovascular form is a serious disease which produces legal blindness in many patients with poor prognosis if left untreated. We intend to establish a clinical guide with the different therapeutic options that exist nowadays, which may help the ophthalmologists in their clinical practice. METHODS: A group of medical retina experts selected by SERV have evaluated the results of different published studies with the drugs currently available, obtaining an evidence-based consensus. Some recommendations have been established for diagnosis, treatment and monitoring of patients with neovascular ARMD. RESULTS: The intravitreal injection of ranibizumab at a dosage of 0.5 mg produces significant improvement of visual acuity in subfoveal lesions, according to data obtained from studies with the highest level of evidence. It should be considered as a first choice drug. The use of bevacizumab, a drug with not approved indication for intraocular use, nor for the treatment of neovascular ARMD can reach a result which is closer to the ones obtained with ranibizumab than to those obtained with photodynamic therapy (PDT) and pegaptanib. The use of intravitreal pegaptanib sodium in intravitreal injection at a dosage of 0.3 mg as a treatment for subfoveal lesions can obtain similar results to the TFD, but with a wider range of injuries. CONCLUSION: The results of the evidence-based studies are a good guide for the treatment of this disease.

Guías de práctica clínica de la SERV: tratamiento de la degeneración macular asociada a la edad (DMAE) exudativa / Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD)

Objetivo: La Degeneración Macular Asociada a laEdad (DMAE) en su forma húmeda supone unagrave enfermedad que condiciona ceguera legal enmuchos pacientes y con mal pronóstico si no es tratada.Pretendemos establecer una guía de actuaciónclínica con las diferentes opciones terapeúticas queexisten en el momento actual, que puedan ayudar aloftalmólogo en su práctica clínica.Métodos: Un grupo de expertos en retina médicaseleccionados por la SERV han evaluado los resultadosde los diferentes estudios publicados con losfármacos actualmente disponibles, llegando a un consenso basado en la evidencia. Se han establecidounas recomendaciones para el diagnóstico, tratamientoy seguimiento de los enfermos con DMAEhúmeda.Resultados: La inyección intravítrea de ranibizumaba la dosis de 0,5 mg permite obtener mejoríassignificativas de la agudeza visual en lesiones subfoveales,según los datos obtenidos de estudios conmáximo nivel de evidencia. Debe ser consideradocomo el fármaco de primera elección. El empleo debevacizumab, fármaco sin indicación aprobada parauso intraocular, ni para el tratamiento de la DMAEhúmeda, puede aportar un beneficio más próximo alos resultados obtenidos con el ranibizumab que alos obtenidos con la terapia fotodinámica (TFD) yel pegaptanib. El uso de pegaptanib sódico eninyección intravítrea a la dosis de 0,3 mg como tratamientode lesiones subfoveales permite obtenerresultados parecidos a la TFD, pero en un abanicomás amplio de lesionesConclusiones: Los resultados de los estudios basadosen la evidencia constituyen una buena guía deactuación en el tratamiento de esta enfermedad(AU)

Objective: Age related macular degeneration(ARMD) in its neovascular form is a serious diseasewhich produces legal blindness in many patientswith poor prognosis if left untreated. We intend toestablish a clinical guide with the different therapeuticoptions that exist nowadays, which may helpthe ophthalmologists in their clinical practice.Methods: A group of medical retina experts selectedby SERV have evaluated the results of differentpublished studies with the drugs currently available,obtaining an evidence-based consensus. Somerecommendations have been established for diagnosis, treatment and monitoring of patients with neovascularARMD.Results: The intravitreal injection of ranibizumabat a dosage of 0.5 mg produces significant improvementof visual acuity in subfoveal lesions, accordingto data obtained from studies with the highestlevel of evidence. It should be considered as a firstchoice drug. The use of bevacizumab, a drug withnot approved indication for intraocular use, nor forthe treatment of neovascular ARMD can reach aresult which is closer to the ones obtained with ranibizumabthan to those obtained with photodynamictherapy (PDT) and pegaptanib. The use of intravitrealpegaptanib sodium in intravitreal injection at adosage of 0.3 mg as a treatment for subfoveallesions can obtain similar results to the TFD, butwith a wider range of injuries.Conclusion: The results of the evidence-based studiesare a good guide for the treatment of this disease(AU)

Charmed-meson decay constants in three-flavor lattice QCD.

We present the first lattice QCD calculation with realistic sea quark content of the D+-meson decay constant f(D+). We use the MILC Collaboration's publicly available ensembles of lattice gauge fields, which have a quark sea with two flavors (up and down) much lighter than a third (strange). We obtain f(D+)=201+/-3+/-17 MeV, where the errors are statistical and a combination of systematic errors. We also obtain f(Ds)=249+/-3+/-16 MeV for the Ds meson.

Historia de evolución / History of evolution

No disponible

No disponible

Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation.

OBJECTIVES: We tested the hypothesis that the response to flecainide infusion can identify patients with atrial fibrillation (AF) in whom the hybrid pharmacologic and ablation therapy reduces the recurrences of AF. BACKGROUND: Infusion of class IC anti-arrhythmic drugs may promote transformation of AF into atrial flutter. Catheter ablation of atrial flutter has been demonstrated to be highly effective in preventing recurrences of atrial flutter. METHODS: Seventy-one consecutive patients with paroxysmal or chronic AF, in whom flecainide infusion (2 mg/kg body weight, intravenously) determined the transformation of AF into common atrial flutter (positive response), were randomized to receive one of the following treatments: oral pharmacologic treatment with flecainide (group A, n = 23); the hybrid treatment (catheter ablation of the inferior vena cava-tricuspid annulus isthmus, plus oral flecainide) (group B, n = 24); or catheter ablation of the isthmus only (group C, n = 24). Thirty-seven patients with a negative response to flecainide, who chose to be submitted to the hybrid treatment, were selected as the control group (group D). RESULTS: During a mean follow-up period of 24 +/- 7.2 months, the recurrences of AF and atrial flutter in group B (42%) were significantly lower than those in group A (78%, p < 0.001), group C (92%, p < 0.001) and group D (92%, p < 0.001). CONCLUSIONS: The creation of a complete bi-directional conduction block at the inferior vena cava-tricuspid annulus isthmus, plus flecainide administration, reduces the recurrences of both AF and atrial flutter in patients with class IC atrial flutter. Moreover, the early response to flecainide is safe and reliable in identifying patients who may benefit from this therapy.

Dipyridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test.

OBJECTIVES: Many different stress echocardiographic and radionuclide perfusion imaging tests have been proposed for detecting epicardial coronary artery disease (CAD) in hypertensive patients. Their relative diagnostic and prognostic value has not been exactly established. BACKGROUND: A positive exercise electrocardiography test has a low diagnostic specificity in hypertensive patients and warrants for a complementary imaging test to confirm the diagnosis of coronary artery disease. METHODS: Hypertensive patients (n = 53), (29 males, aged 58 +/- 10 years) with normal left ventricular function detected by echocardiography and previous positive exercise test ( > or = 0.15 mV of ST segment depression on 12 lead electrocardiogram) underwent dipyridamole-atropine stress echocardiography (DASE) and thallium-201 stress/ rest myocardial single-photon emission computed tomography (SPECT). All patients had coronary angiography within 15 days and independently of imaging test results. RESULTS: Coronary angiogram showed significant ( > or = 50% qualitatively assessed diameter reduction) epicardial coronary artery disease in 23 (43%) patients. Sensitivity for detection of coronary artery disease was significantly higher for scintigraphy (DASE = 78% versus SPECT = 100%, P < 0.05) while specificity was higher for echo (DASE = 100% versus SPECT = 47%, P < 0.00001). Diagnostic accuracy was also higher for echo (DASE = 91% versus SPECT = 70%, P < 0.01). CONCLUSION: In patients with exercise-nduced ST segment depression, dipyridamole stress echo and SPECT perfusion scintigraphy are both good diagnostic options, with DASE characterized by higher specificity, lower sensitivity, and at least comparable diagnostic accuracy than SPECT.

[The echo-stress test with dipyridamole-atropine on the 3rd-5th day of an uncomplicated acute myocardial infarct for risk stratification and early discharge]. / Eco-stress con dipiridamolo-atropina in terza-quinta giornata nell'infarto miocardico acuto non complicato per la stratificazione del rischio e la dimissione precoce.

BACKGROUND: The aim of this study was to evaluate if dipyridamole-atropine stress echocardiography (DASE) performed between the third-fifth day in uncomplicated acute myocardial infarction allows for an effective risk stratification with an early discharge in some cases. METHODS: Between February 1997 and September 1998, 190 patients (138 males and 52 females, mean age 59 +/- 10.3 years), with acute myocardial infarction, were enrolled in the study. DASE was performed between the third-fifth day with a dipyridamole infusion of 0.84 mg/kg over 10 min followed by 1 mg of atropine from the twelfth to the fifteenth minute. DASE was considered positive in the presence of a new or worsening dyssynergy. Patients with heart failure, angina, major arrhythmias, and poor acoustic window were excluded. In the follow-up spontaneous events were defined as cardiac death, non-fatal myocardial reinfarction, unstable angina or heart failure (with hospitalization). RESULTS: DASE was performed in 92 patients (48.4%), all without complications: 29 patients (31.5%) had a negative DASE result, and 63 patients (68.5%) had a positive DASE. The average hospital stay of patients with a negative test was significantly lower in comparison with that of patients with a positive test (7.55 +/- 1.32 vs 9.29 +/- 1.61 days, p < 0.0001). Events occurred in 19 patients (20.6%), 2/29 patients with a negative DASE (6.9%), 17/63 patients with a positive DASE (27%), 6/43 patients with homozonal positivity after atropine or high-dose dipyridamole (14%), 11/20 patients with heterozonal positivity or homozonal positivity after low-dose dipyridamole (55%). On univariate analysis the variables significantly associated with spontaneous events were: age (chi 2 = 6.41, p = 0.019), left ventricular ejection fraction at rest (chi 2 = 8.89, p = 0.004), number of asynergic segments after stress (chi 2 = 6.87, p = 0.010), increase in the number of asynergic segments after stress (chi 2 = 4.01, p = 0.039), wall motion score index after stress (chi 2 = 9.60, p = 0.003), increase in wall motion score index after stress (chi 2 = 3.60, p = 0.049), DASE positivity (chi 2 = 4.89, p = 0.029), homozonal positivity after low-dose dipyridamole (chi 2 = 8.57, p = 0.013), heterozonal positivity (chi 2 = 13.10, p = 0.001). On Cox's multivariate analysis independent predictors of events were: age (relative risk 3.92, p = 0.0146), DASE positivity (relative risk 1.79, p = 0.0054). CONCLUSIONS: DASE between the third-fifth day in uncomplicated acute myocardial infarction is feasible, tolerable, safe, and effective for early risk stratification. A negative DASE detects a "very low-risk" patient group, and allows for an earlier hospital discharge, without an increased risk of events. The heterozonal positivity or the homozonal positivity after low-dose dipyridamole indicates the need for a coronarography, due to the high risk of events at follow-up.

[Dipyridamole-echocardiography and thallium exercise myocardial scintigraphy in the diagnosis of obstructive coronary or microvascular disease in hypertensive patients with left ventricular hypertrophy and angina]. / Eco-dipiridamolo e miocardioscintigrafia da sforzo al tallio nella diagnosi di coronaropatia ostruttiva o malattia microvascolare in pazienti ipertesi con ipertrofia ventricolare sinistra e angina.

BACKGROUND: Hypertensive patients with left ventricular hypertrophy can be affected with angina pectoris for significant epicardial coronary stenosis or microvascular disease with normal coronarography. Exercise-electrocardiography test is positive in both conditions. The aim of the present study was to assess the accuracy of dipyridamole-echocardiography test and thallium exercise myocardial scintigraphy in the diagnosis of epicardial coronary stenosis or microvascular disease in hypertensive patients with left ventricular hypertrophy and angina pectoris. METHODS: Forty-two hypertensive patients (22 males, age 40-76 years, mean 58.6 +/- 10.1), with left ventricular hypertrophy, typical angina pectoris, ischemia that can be induced by exercise-electrocardiography test, without previous myocardial infarction, myocardial revascularization or diabetes mellitus, underwent dipyridamole-echocardiography test, thallium exercise myocardial scintigraphy and coronarography. Dipyridamole-echocardiography test was performed with dipyridamole (0.56 mg/kg over 4 minutes, followed by 0.28 mg/kg from the 8th to the 10th minute) + atropine (1 mg from the 12th to 15th min.) and was positive for a transient dyssynergy of contraction of at least 2 myocardial segments; the left ventricle was divided into 16 segments. SPECT thallium myocardial scintigraphy was performed after bicycle exercise and then three hours later, and it was positive for reversible uptake defects of at least 2 segments with a 22-segment model. Coronarography was performed with Judkin's technique and was positive if at least one large epicardial vessel was narrowed by more than 50%. RESULTS: Coronarography: normal in 25 cases (59.5%, 8 males), pathologic in 17 (40.5%, 14 males): left main coronary artery in 1 (5.9%), three vessels in 5 (29.4%), two vessels in 3 (17.7%), 1 vessel in 8 (47%). Dipyridamole-echocardiography-test: positive in 15 cases (35.7%), negative in 27 (64.3%); sensitivity 88.2%, specificity 100%, diagnostic accuracy 95.2%, positive predictive value 100%, negative predictive value 92.6%. Thallium exercise myocardial scintigraphy: positive in 30 cases (71.4%), negative in 12 (28.6%); sensitivity 100%, specificity 48%, diagnostic accuracy 69%, positive predictive value 56.7%, negative predictive value 100%. CONCLUSIONS: Dipyridamole-echocardiography test has higher diagnostic accuracy and when positive, it predicts significant epicardial coronary stenosis. It can be less sensitive in one-vessel patients (2 false negatives were stenosis 75% of left anterior descending and 60% of 1st diagonal). Thallium exercise myocardial scintigraphy is complementary because when negative, it excludes epicardial coronary stenosis and confirms microvascular disease. In hypertensive patients with left ventricular hypertrophy and suspected angina pectoris, the following flow-chart may be proposed: the first test is exercise-electrocardiography test. Only those who are positive at low-to-intermediate workload then undergo dipyridamole-echocardiography test. Those who are positive in this then undergo coronarography, while the negative ones undergo thallium exercise myocardial scintigraphy. Those who are positive at thallium exercise myocardial scintigraphy perform the coronarography, while cases with negative results do not undergo further diagnostic tests since they are affected with microvascular disease.